ESG management targets

Our management targets covering environmental, social and governance (ESG) topics are integrated throughout our strategy. Topics covered include access to medicines, global health challenges, environmental sustainability and ethical business practices. Relevant information is disclosed in this report within the strategic priority sections as outlined below.

Deliver transformative innovation

Innovation for global health

  • Advance clinical development programs for our next-generation antimalarials and for patients with Chagas-related heart failure

Diverse clinical trials

  • Evaluate diversity and inclusion principles for 100% of Phase III studies with US country participation (with a longer-term goal to increase and embed this evaluation throughout our global trials)

Embrace operational excellence

Third-party risk management

  • Conduct risk assessments for all new eligible suppliers

Unleash the power of our people

Diversity and inclusion

  • Close the gender pay gap by 2023
  • Achieve gender balance in management by 2023

Learning and development

  • Invest USD 100 million in learning over five years from 2019

Build trust with society

Access and global health

  • Implement an access strategy for all new medicines launched
  • Implement tiered pricing for launches in our Pharmaceuticals and Oncology business units based on national income levels and value-based pricing
  • Increase by at least 200% patients reached with strategic innovative medicines in low- and middle-income countries (LMICs) by 2025 (compared with 2019)
  • Increase by at least 50% the number of patients reached with Novartis flagship programs in LMICs by 2025 (compared with 2019)

Ethical business practices

  • Post all clinical trial results on www.clinicaltrials.gov or www.novartisclinicaltrials.com within one year of completion
  • Integrate human rights into third-party risk assessments in scope
  • Enhance external reporting on anti-bribery

Environmental sustainability1

Emissions:
  • Be carbon neutral in our own operations (Scope 1 and 2) by 2025 and across the value chain (Scope 1, 2 and 3) by 2030
  • Achieve net zero carbon emissions across our value chain by 2040
  • Include environmental criteria in all supplier contracts by 2025
Water:
  • Reduce water consumption in our own operations by half by 2025 (compared with 2016), with no water quality impacts from the manufacturing of our products
  • Become water neutral in all areas of our operations by 2030 while enhancing water quality wherever we operate
Waste:
  • Eliminate polyvinyl chloride in packaging by 2025 (secondary and tertiary packaging; primary packaging when feasible)
  • Reduce the amount of waste sent for disposal by half by 2025 (compared with 2016)
  • Become plastic neutral by 2030, with all new products meeting sustainable design principles

1 Additional information on environmental sustainability in our manufacturing operations and supply chain can be found in section "Transforming manufacturing" and "Managing our supply chain responsibly", respectively. Information relevant to the Task Force on Climate-related Financial Disclosures (TCFD) is in section "TCFD disclosure".